Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G0EG
|
|||
| Drug Name |
PMID26560530-Compound-15
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ALVINE PHARMACEUTICALS, INC. PHARMIX CORPORATION GRIFFIN, John LANZA, Guido BOARDMAN, Paul SPENCER, Andrew
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H10N2O4
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1CC3=CC4=C(C=C3)NC(=O)C4=O)C(=O)C(=O)N2
|
|||
| InChI |
1S/C17H10N2O4/c20-14-10-6-8(1-3-12(10)18-16(14)22)5-9-2-4-13-11(7-9)15(21)17(23)19-13/h1-4,6-7H,5H2,(H,18,20,22)(H,19,21,23)
|
|||
| InChIKey |
ZWPNSXUXJWRFIZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.